H.Lundbeck (HLUYY.PK)
isn't going to be an especially familiar name for many readers, as this
Danish pharmaceutical company has largely sold through licensing
partners in the United States. That said, this CNS specialist was the
brains behind Forest Labs' (FRX)
highly successful depression drug Lexapro, and the company has some
particularly interesting drugs in its pipeline. While the company's
go-to-market strategy is still a work in progress and patent expirations
are likely going to cut deeply into cash flows in the short term, this
looks like a potentially undervalued name to consider.
Please read the full article here:
Lundbeck Could Cheer Up Patient Investors
No comments:
Post a Comment